PeriVision
PeriVision's VisionOne is a Swiss VR visual field platform for glaucoma. Its patented SORS algorithm cuts perimetry to two or three minutes per eye, streaming results to a cloud dashboard for ophthalmologists and optometrists.
What is PeriVision?
PeriVision is a Swiss medical technology company whose product, VisionOne, is a visual field testing platform built on three technologies at once: artificial intelligence, virtual reality and cloud computing. It addresses perimetry, the examination that maps how much of the visual field a patient can still see, and which is the backbone of diagnosing and monitoring glaucoma. Conventional perimetry runs on bowl-shaped table instruments weighing around 25 kilograms, which need a dedicated room kept dark, a chin rest, an eye patch and a technician watching the patient throughout. VisionOne replaces that with a 0.6 kilogram VR headset that can be used anywhere in a practice.
The interesting part is not the headset but the algorithm behind it. SORS, the Sequentially Optimized Reconstruction Strategy, is a patented AI meta-strategy trained on thousands of visual field tests. Rather than probing every location, it evaluates a subset of points, typically twenty or thirty-six, then reconstructs the untested locations from linear approximation and learned correlations between retinotopic positions. The result is a test that runs 60 to 70 percent faster than the traditional SITA Standard strategy, bringing roughly eleven minutes down to two or three minutes per eye, while holding a mean defect correlation of R = 0.91 with the clinical gold standard.
Around that core sit the things a clinic actually needs: several testing strategies including screening, normal, dynamic and supra-threshold modes; the usual patterns from 10-2 and 24-2 through 30-2, G, Esterman and C-40; sensor-based eye tracking for fixation control; an automated multi-language voice assistant that instructs the patient so a technician need not hover; a custom lens holder for corrective lenses; and standardised PDF export for hospital records. Technicians schedule and configure tests in one dashboard, clinicians read results in another, with the cloud in between.
The company is a spin-off of the University of Bern and its university hospital, incorporated in Switzerland in 2022. VisionOne carries CE marking, FDA registration and MHRA certification, and the site states it is available in the United States, United Kingdom and European Union.
What it does
- Run a full visual field examination on a portable VR headset, with no darkened room and no eye patch
- Cut testing time to roughly two or three minutes per eye using the patented SORS strategy
- Guide the patient through the test with an automated multi-language voice assistant
- Schedule and configure examinations for each patient from the Technician Dashboard
- Review, compare and interpret results in the Clinician Dashboard once they sync to the cloud
- Monitor gaze fixation in real time through sensor-based eye tracking
- Export exam results as standardised PDFs into hospital and electronic health record systems
When to use PeriVision / When not to
A quick filter to help you decide if PeriVision is the right fit.
When to use PeriVision
- Glaucoma specialists and ophthalmology clinics running high volumes of visual field tests
- Community optometrists who want perimetry without dedicating a darkened room to it
- Practice managers trying to raise functional testing capacity without hiring staff or adding rooms
- Clinicians treating elderly or frail patients who struggle with chin rests, eye patches and room transfers
- Clinical research teams and biopharma sponsors needing portable, reproducible visual field endpoints
When not to use PeriVision
- Individuals looking to check their own eyesight: this is a prescription medical device sold to professionals
- Buyers who need a published price, a free plan or a self-service trial before committing
- Developers expecting a public API, mobile apps or online technical documentation
- Practices needing visual acuity, contrast sensitivity, colour vision or Amsler testing today, since those remain announced rather than shipped
- Organisations outside the jurisdictions covered by the FDA, CE and MHRA registrations, where availability is not established
How to use PeriVision
A typical end-to-end flow, from setup to results.
- Read the product page or download the product brochure to check the strategies and patterns against your clinical needs
- Use the contact form, selecting Demo Requests, to arrange a demonstration
- Request a quotation through the same form or the Order now button, since no price is published
- Agree the order in writing, since quotations are non-binding until PeriVision issues an invoice, an order confirmation or delivers
- Pay in advance unless a different arrangement is agreed in writing
- Inspect the hardware on arrival and report any visible damage within seven days
- Nominate an internal contact to act as first-level support, ideally with access to a remote maintenance tool
- Schedule and configure each patient's test in the Technician Dashboard, then fit the headset
- Let the voice assistant guide the patient through the examination, from any chair in the practice
- Open the synced results in the Clinician Dashboard and export standardised PDFs into your record system
Pros & Cons
Pros
- Test time drops to roughly two or three minutes per eye against about eleven minutes for SITA Standard
- Test-retest variability falls 26 to 39 percent against the Dynamic Strategy, at 1.30 dB versus 1.71 dB for SITA
- Strong published agreement with reference devices: mean sensitivity and mean defect correlations of 0.91 and 0.90 against an Octopus 900 across one hundred eyes
- Thirteen peer-reviewed papers and conference presentations listed, including Ophthalmology Science, PLOS ONE and Translational Vision Science & Technology
- High patient acceptance, with 95 percent finding the system easy to use in a clinical study and 96 percent rating the experience good or very good in a Geneva case study
- A 0.6 kilogram headset removes the darkened room entirely, and one clinic reports roughly 40 percent more functional testing capacity without extra staff or space
- Regulatory coverage across three jurisdictions at once, with CE marking, FDA registration and MHRA certification
Cons
- No price is published anywhere: no pricing page, no range, no plans, everything goes through a quotation
- No free trial and no free plan are advertised, and hardware must be purchased alongside the software subscription
- Functional scope is still limited to the visual field, since visual acuity, contrast sensitivity, colour vision and the Amsler grid remain announced as coming soon
- No public API, no mobile application and no online technical documentation
- No hosting country or region is named for the clinical platform, and no subprocessor list is published for it
- Retention periods are deferred to an unpublished internal policy, with no figure given
- The site shows signs of neglect: two unedited placeholders remain, the footer copyright is frozen at 2024, and the general terms name the publisher PeriVision Ltd. where the imprint says PeriVision SA
Pricing & Plans
No price is published. PeriVision operates no free plan and advertises no free trial: the site carries no pricing page at all, and both the Order now and Book a demo buttons lead to the contact form, so every figure comes from a quotation. The general terms indicate only that all prices are stated in Swiss francs (CHF), exclusive of taxes and duties, that quotations are non-binding until an invoice or order confirmation is issued, and that orders require advance payment. The product page implies a hardware purchase combined with a software subscription, but gives no amount for either.
Data, GDPR & hosting
A consolidated view of how PeriVision handles your data.
GDPR overview
Concrete, and more detailed than most vendors publish. The notice claims compliance with both the GDPR and Swiss data protection law, and names an Article 27 EU representative: International Associates Auditing & Certification Limited, The Black Church, St Mary's Place, Dublin 7, Ireland, contact person Martin Coles, martin@ia-EU.com. Klaus Hammer, Head of Regulatory, is the company contact for incidents. Transfers outside Switzerland or the EU rely on Standard Contractual Clauses. PeriVision claims Privacy by Design with minimal collection and pseudonymisation, encryption in transit, access controls, regular audits and backups, and states that it runs a Data Protection Impact Assessment because health data is highly sensitive. Breaches are notified to the supervisory authority within 72 hours in the EU, or as soon as possible in Switzerland. No Article 37 Data Protection Officer is named, and no subprocessor list is published for the clinical platform.
Who owns the data?
PeriVision's privacy notice, last updated on 2 September 2025, describes three categories of data: patient clinical data such as test results, visual field measurements and eye-tracking traces; user account data covering clinician and technician names, credentials and contact details; and technical usage data including device identifiers, logins, timestamps and IP addresses. Processing rests on explicit consent for sensitive health data, on contract performance for delivering VisionOne, and on legal obligations and legitimate interests. Data subjects may request access, rectification, erasure, restriction, objection and portability by writing to privacy@perivision.com, with a reply promised within thirty days in Switzerland or one month in the EU. The notice never states outright who owns the data.
Reuse rights
PeriVision states that clinical data serves diagnostics, insights and clinical decision support, that account data provides access to VisionOne and manages users and communications, and that technical data covers platform operation, security, troubleshooting and analytics. Sharing is confined to authorised processors such as cloud hosting and analytics providers, bound by formal data processing agreements, and to regulatory agencies where the law requires it. Clause 30 of the general terms adds that PeriVision will not sell or lease personal information to third parties without permission or a legal obligation. On the customer side, exam results are exported as standardised PDFs for hospital systems, and nothing on the site restricts what a clinic may then do with the reports it holds on its own patients. The site never addresses whether customer or patient data is used to train AI models, and documents no opt-out.
Data retention & training
Hosting summary
PeriVision states that VisionOne runs on cloud infrastructure compliant with the GDPR and Swiss law, and that where data is transferred outside Switzerland or the EU appropriate safeguards such as Standard Contractual Clauses are applied. That phrasing implies Switzerland and the EU as the reference perimeter without ever committing to it. No provider, no country and no region is named for the clinical platform, and no subprocessor list is published for it. Security measures claimed are encryption in transit, access controls, regular audits and backups; encryption at rest is not mentioned. A Data Protection Impact Assessment is carried out because of the sensitivity of the health data involved. Separately, the marketing website is hosted by Wix, which DNS resolution confirms, but that says nothing about where clinical records live. Any clinic with a data residency requirement should ask PeriVision directly and get the answer in the contract.
Things to keep in mind
Risks and trade-offs to weigh before adopting PeriVision.
- Diagnostic deskilling: a faster, guided test invites more frequent use, and clinicians should keep interpreting fields rather than trusting a reconstructed map by default
- SORS infers untested locations from learned correlations, so a reconstructed point is a statistical estimate and not a measurement, which matters in atypical or advanced disease
- The site's own figures are inconsistent between pages, quoting 1.30 dB test-retest variability on the product page and 0.09 dB in a case study, and one key correlation is marked as a forthcoming publication
- Highly sensitive health data leaves the practice for a cloud whose hosting country is never named and whose subprocessors are never listed
- Nothing on the site states whether patient clinical data is used to train the AI models, and no opt-out is documented
- Retention is deferred to an unpublished internal policy, so a clinic cannot tell how long patient data will be held
- Vendor lock-in is real: the hardware, the algorithm and the cloud come as one package, and results leave only as PDFs
Setup & Integrations
Technical difficulty
Moderate, and more logistical than technical. There is no self-service sign-up: access begins with a quotation, then a hardware delivery that must be inspected within seven days. The customer names an internal contact to act as first-level support, ideally with remote maintenance access, and a twelve-month service interval applies. Daily use is markedly simpler than conventional perimetry, with no darkened room, chin rest, eye patch or touchscreen calibration, and a voice assistant guiding the patient. One published case study describes two years of gradual adoption alongside an existing perimeter rather than an immediate switch.
Deployment
Behind PeriVision
Fundraising
Social
Resources
All the official URLs gathered for verification and reference.
Alternatives
Tools that compete with or complement PeriVision.
Frequently asked questions
What exactly is VisionOne?
Who is it designed for?
How long does a test take?
Is it as reliable as a conventional perimeter?
How much does it cost?
Is there a free trial?
Is the device certified?
Is there an API or a mobile app?
Is patient data used to train AI models?
Does it need a darkened room or a network connection?
Should you pick PeriVision?
VisionOne is one of the more credible pieces of clinical AI in this directory, and the reason is evidence rather than marketing. PeriVision lists thirteen peer-reviewed papers and conference presentations, publishes correlation figures against reference perimeters, and carries CE marking, FDA registration and MHRA certification simultaneously. The case studies do not stop at laboratory numbers: a Geneva clinic reports roughly 40 percent more functional testing capacity without adding staff or rooms, and an examination that fell from twenty-five minutes to about ten. For a glaucoma practice bottlenecked on its darkened room, that is a concrete operational argument.
The reservations are commercial and documentary rather than clinical. Nothing about the price is public, so the buying process starts with a quotation and a hardware purchase, and no trial exists to shorten the decision. The functional scope is still the visual field alone; acuity, contrast, colour vision and the Amsler grid are announced, not shipped. On the data side the privacy notice is unusually detailed for a company this size, with a named Article 27 representative, Standard Contractual Clauses and a documented impact assessment, yet it names no hosting country, publishes no subprocessor list for the clinical platform, gives no retention figure, and says nothing at all about whether patient data trains the models.
The site itself shows a young company moving faster than its web pages: two unedited placeholders survive, the footer copyright is stuck at 2024, and the general terms call the publisher PeriVision Ltd. where the imprint says PeriVision SA. None of that undermines the product, but it does mean a buyer should get the commercial and data-processing answers in writing rather than from the website.
- Choosing a selection results in a full page refresh.
- Opens in a new window.